333 related articles for article (PubMed ID: 18550016)
1. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of preoperative plasma levels of big endothelin-1 to prognosis of gastric carcinoma].
Teng XJ; Liu R; Zhang ZX; He JF; Shen ZX
Ai Zheng; 2008 Jan; 27(1):88-91. PubMed ID: 18184472
[TBL] [Abstract][Full Text] [Related]
3. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma.
Mai HQ; Zeng ZY; Zhang CQ; Feng KT; Guo X; Mo HY; Deng MQ; Min HQ; Hong MH
Cancer; 2006 Apr; 106(7):1548-53. PubMed ID: 16518816
[TBL] [Abstract][Full Text] [Related]
4. Raised levels of plasma big endothelin 1 in patients with colorectal cancer.
Simpson RA; Dickinson T; Porter KE; London NJ; Hemingway DM
Br J Surg; 2000 Oct; 87(10):1409-13. PubMed ID: 11044168
[TBL] [Abstract][Full Text] [Related]
5. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
7. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
8. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
[TBL] [Abstract][Full Text] [Related]
9. [Peripheral plasma Big endothelin 1 levels in patients with gastric carcinoma undergoing radical gastrectomy and its relationship with tumor recurrence].
Teng XJ; Shen ZX; Xiang JJ; Shen L; Yuan L; Guo J; Wang XL
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan; 9(1):34-7. PubMed ID: 16437368
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
11. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
12. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
[TBL] [Abstract][Full Text] [Related]
16. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
17. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up.
Wülfing P; Diallo R; Kersting C; Wülfing C; Poremba C; Rody A; Greb RR; Böcker W; Kiesel L
Clin Cancer Res; 2003 Sep; 9(11):4125-31. PubMed ID: 14519635
[TBL] [Abstract][Full Text] [Related]
18. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer.
Hebbar M; Révillion F; Louchez MM; Vilain MO; Fournier C; Bonneterre J; Peyrat JP
Clin Cancer Res; 1998 Feb; 4(2):373-80. PubMed ID: 9516925
[TBL] [Abstract][Full Text] [Related]
19. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.
Coskun U; Günel N; Toruner FB; Sancak B; Onuk E; Bayram O; Cengiz O; Yilmaz E; Elbeg S; Ozkan S
Neoplasma; 2003; 50(1):41-6. PubMed ID: 12687277
[TBL] [Abstract][Full Text] [Related]
20. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
